Diabetes Obes Metab (2017) 19(10):143645
GLP-1 receptor agonists are distinct from many other weight loss medications because they work through hormonal signaling rather than stimulation or suppression alone
It is not an FDA-approved finished product, and the FDA states that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed, and that compounded drugs are not the same as generic drugs, which must establish therapeutic equivalence under section 505(j)
Tesamorelin has direct, clinical-trial evidence for visceral fat reduction in a specific population (HIV lipodystrophy)
doi: 10.3389/fendo.2025.1615516 Received 21 April 2025 Accepted 04 August 2025 Published 26 August 2025 Volume 16 - 2025 Edited by Yoshifumi Saisho, Saisho Diabetes Clinic, Japan Reviewed by Sudhanshu Kumar Bharti, Patna University, India William J